Under pressure from the Biden administration, Johnson & Johnson has decided not to alter payment methods for some hospitals that participate in a federal drug discount program.
The move came after the U.S. Health and Resources Administration last week threatened the health care giant with sanctions if it proceeded with plans to issue rebates for two widely prescribed medicines instead of offering discounted prices under the 340B program.
Last month, J&J announced it would change payment terms for its Xarelto blood thinner and the Stelara plaque psoriasis treatment through the discount program, which was created to help hospitals and clinics care for low-income and rural patients. To ensure the program achieves this goal, drug companies that want to take part in Medicare or Medicaid must offer their medicines at a discount — typically, 25% to 50%, but sometimes higher — to participating hospitals and clinics.
Click this link for the original source of this article.
Author: Ed Silverman
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
